Calidi Biotherapeutics has raised $6,000,000 in a recent funding round, the company announced today. This capital infusion will support its ongoing work as a clinical-stage biopharmaceutical company focused on revolutionizing oncolytic viral therapies with stem cell-based platforms. The investment underscores a commitment to advancing innovative approaches in cancer treatment.
Calidi Biotherapeutics specializes in developing advanced treatments that utilize specially engineered viruses to selectively target and eliminate cancer cells, while minimizing impact on healthy tissues. By integrating these oncolytic viruses with proprietary stem cell delivery systems, the company aims to enhance the precision and effectiveness of its therapeutic interventions. This funding round highlights investor confidence in the potential of Calidi Biotherapeutics’ technology to address critical challenges in oncology and provide new solutions for patients.
The newly secured $6,000,000 will primarily be directed towards supporting the company’s ongoing research and development programs. Calidi Biotherapeutics plans to use the funds for strategic growth initiatives, including the progression of its pipeline candidates through various stages of clinical development. A portion of the funding is also expected to facilitate the expansion of its scientific and operational capabilities, bolstering its capacity for innovation in the biopharmaceutical sector.
This financial milestone is expected to accelerate Calidi Biotherapeutics’ efforts to advance its innovative therapies closer to patients. The company remains committed to its long-term vision of transforming cancer treatment through advanced biological platforms and is poised for continued strategic growth and development within the dynamic biopharmaceutical landscape.
